Personalized cell therapies hold extraordinary promise, but getting them to patients faster requires tackling unprecedented complexity in manufacturing, scale-up, and global delivery. This independent thought-leadership session brings together leaders from DFCI, CTMC, and Cellipont (moderated by Marcia Blackmoore of L7 Informatics) for a principled, idea-driven discussion on the future of advanced therapies. Together, they will explore the speed imperative, the human impact of delays, and the role of a connected digital backbone in transforming today’s breakthroughs into tomorrow’s cures. With diverse perspectives across science, operations, and clinical delivery, the panel will offer clear, actionable insights for how the field can move from promise to global impact.
Chair:
Marcia Blackmoore, Chief Commercial Officer, L7 Informatics
Speakers:
Jason Bock, Ph.D., Founder and CEO, CTMC
Carolyn Lutzko, Ph.D., Scientific Director, Novel Cell Therapy, Dana-Farber Cancer Institute
Daniel Ramirez, Vice President Operations, Site Head, Cellipont Bioservices
To access this resource, please make sure to accept cookies.